Academician Xu Zhang’s Team Showcases the Expertise of Chinese Urology at the SRS World Robotic Surgery Society

Academician Xu Zhang’s Team Showcases the Expertise of Chinese Urology at the SRS World Robotic Surgery Society

In the winter along the Neckar River, Heidelberg's old town was adorned in snow, providing a fitting backdrop for an academic atmosphere rich in culture and freedom. The "Semi-Live 2024" International Urology Conference and the CGAU Academic Annual Meeting between China and Germany were successfully held from January 18 to 20 in Heidelberg, a hub of European academia. Top urological experts from over 10 countries, including Germany, China, the United States, the United Kingdom, Italy, Spain, India, and Egypt, attended. Notable participants included Professor Markus Hohenfellner, Chair of Urology at the University of Heidelberg, Professor Vito Pansadoro, Chair of the European Laparoscopic and Robotic Surgery Challenge Congress, Professor Richard Hautmann, pioneer of the "orthotopic ileal neobladder procedure," Professor Sascha Pahernik, Director of Urology at Nuremberg Hospital, Professor Liqiu Zhou from Peking University, and Professor Shuo Wang from The First Affiliated Hospital, Zhejiang University School of Medicine.
News Express | Physical Function Changes in Pediatric Patients Before and After Hematopoietic Stem Cell Transplantation

News Express | Physical Function Changes in Pediatric Patients Before and After Hematopoietic Stem Cell Transplantation

The "News Express" column aims to bridge the gap between cutting-edge research and clinical practice, allowing every hematology enthusiast and professional to quickly capture industry trends, spark innovative thinking, and broaden professional horizons. Hematology Frontier carefully selects the latest hematology research findings from top global journals, delivering every brilliant spark of science and clinical practice to you. We invite you to follow this column and join global hematology experts on the journey of scientific exploration!
Dr. Jianyong Li: Advances in Research on Nodal T-Follicular Helper Cell Lymphoma (nTFHL)

Dr. Jianyong Li: Advances in Research on Nodal T-Follicular Helper Cell Lymphoma (nTFHL)

Angioimmunoblastic T-cell lymphoma (AITL), as a major subtype of peripheral T-cell lymphoma (PTCL), poses significant challenges for clinicians due to its complex pathological features, variable clinical presentation, and poor prognosis. In recent years, with advances in medical research, novel diagnostic techniques and treatment methods for nTFHL have emerged, leading to new breakthroughs in diagnosis and therapy. However, patient outcomes remain bleak, underscoring the urgent need for further basic and clinical research to guide clinical practice and improve prognosis. Recently, Dr. Jianyong Li from Jiangsu Province Hospital provided a detailed overview of the latest research progress in nodal T-follicular helper cell lymphoma (nTFHL). Hematology Frontier has compiled these insights for our readers.
Dr. Wenbin Qian: Analyzing the Pros and Cons of CAR-NK Therapy and Future Research Directions

Dr. Wenbin Qian: Analyzing the Pros and Cons of CAR-NK Therapy and Future Research Directions

In the realm of cellular therapy, CAR-NK technology is spearheading a new wave of treatment possibilities. Given the current state of cellular therapy in China, advancing technologies like CAR-NK has become crucial. At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the privilege of inviting Dr. Wenbin Qian from The Second Affiliated Hospital Zhejiang University School of Medicine to provide an in-depth analysis of the benefits and challenges of CAR-NK therapy, explore future research directions, and discuss new chapters in cellular therapy.
Dr. Shenmiao Yang: Navigating the New Era of CLL Treatment with Long-Term and Short-Term Approaches

Dr. Shenmiao Yang: Navigating the New Era of CLL Treatment with Long-Term and Short-Term Approaches

With the widespread adoption of chemotherapy-free treatment regimens and breakthroughs in targeted therapies, chronic lymphocytic leukemia (CLL) treatment has entered a new era. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Shenmiao Yang from Peking University People’s Hospital to provide an in-depth analysis of the current state of CLL treatment in China, discuss future research directions, and explore new chapters in the development of the field.